IFNA2 and COVID-19: Recent clinical trials showed that IFN-α therapy significantly reduced viral shedding and levels of inflammatory biomarkers, whereas IFN-β therapy improved virologic clearance; both therapies led to improved recovery in patients with COVID-19 (68, 69).